DealForma

Biopharma therapeutics and platform venture funding dropped in 2025 compared to 2024, with 435 rounds raising $26B versus 460 rounds and $27.9B in 2024, while the average round size remained stable at $67M ($66M in 2024). Read our research na2.hubs.ly/H04qc740

DealForma is pleased to share that our Founder & CEO, Chris Dokomajilar, will be speaking at the BIO Investment & Growth Summit in Miami Beach on March 3, 2026, during the session “Up Next: M&A and Licensing in the Year Ahead?”. Register here na2.hubs.ly/H03Z7LS0

OrbiMed jumped to the number one spot on this year’s Top 100 biotech venture investors list after more than doubling its deal activity to $5.9 billion in 2025, with the rankings and data compiled and fact-checked by DealForma. Read it here na2.hubs.ly/H03Y6hf0

DealForma is excited to share that our Founder & CEO, Chris Dokomajilar, will be speaking at the 2026: The Top 100 Venture Investors in Biotech webinar on Thursday, February 26, 2026, from 12:00 – 1:00 PM ET hosted by Endpoints News. Register here: na2.hubs.ly/H03RqYx0

Global healthcare and life sciences rebounded in 2025, with 48 IPOs raising $14.1B versus 38 IPOs/$10.2B in 2024. Check out our research na2.hubs.ly/H03Jw6r0

DealForma is pleased to share that our Founder & CEO, Chris Dokomajilar, will be speaking at the BIO Investment & Growth Summit in Miami Beach on March 3, 2026, during the session “Up Next: M&A and Licensing in the Year Ahead?”. Register here na2.hubs.ly/H03JsDK0

DealForma is excited to share that our Founder & CEO, Chris Dokomajilar, will be speaking at the 2026: The Top 100 Venture Investors in Biotech webinar on Thursday, February 26, 2026, from 12:00 – 1:00 PM ET. Register here na2.hubs.ly/H03CBvC0

In 2025, global Healthcare and Life Sciences M&A rebounded decisively, with deal volume rising to 585 transactions and total announced value reaching $269.3 billion, nearly double 2024 levels, supported by stronger pricing and larger upfront commitments. na2.hubs.ly/H03qbC50

AstraZeneca struck a potentially multibillion-dollar obesity and diabetes collaboration with China’s CSPC Pharmaceuticals, paying $1.2B upfront with total deal value possibly exceeding recent blockbusters, making it the largest obesity deal to date. na2.hubs.ly/H03qbtL0

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.

DealForma customers received our quarterly deal and funding charts. Here is a highlight from one of these charts.